Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
133
Completed, industry sponsors, Kidney and urology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed133
133 trials
Showing 1 to 25, recently updated first.
- The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic HyperplasiaPivotal-lookingCompleted
Xintian PharmaceuticalIndustry
NCT05551221 · 110 participants · Start Sep 21, 2022 · Primary completion Sep 10, 2024
Drug: Silodosin Capsules; Tamsulosin · For: Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 8 sites in all
- Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05347693 · 186 participants · Start Mar 24, 2022 · Primary completion Dec 10, 2024
Drug: Sodium Zirconium Cyclosilicate (SZC); Local standard of care · For: Hyperkalaemia; Chronic Kidney Disease
Sites: Bonheiden, Belgium; Leuven, Belgium; Annonay, France · 28 sites in all
- The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPHPivotal-lookingCompleted
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT07134907 · 110 participants · Start Jul 18, 2022 · Primary completion Jul 9, 2024
Drug: Silodosin; Tamsolusin · For: BPH (Benign Prostatic Hyperplasia)
Sites: Hefei, China; Wuhan, China; Suzhou, China · 6 sites in all
BayerBayer (BAYRY)
NCT05705271 · 200 participants · Start Feb 8, 2023 · Primary completion Jul 3, 2025
Drug: Finerenone (Kerendia, BAY94-8862) · For: Chronic Kidney Disease; Type 2 Diabetes Mellitus
Sites: Karnataka, India; Nadiād, India; Faridabad, India · 17 sites in all
- Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.Pivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01093534 · 547 participants · Start Jan 19, 2010 · Primary completion Jun 23, 2011
Drug: Placebo; solifenacin · For: Detrusor Overactivity; Overactive Bladder
Sites: New York, New York; West Reading, Pennsylvania; Graz, Austria · 79 sites in all
- Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)Pivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT02216214 · 888 participants · Start Oct 7, 2014 · Primary completion Nov 29, 2017
Drug: Mirabegron; Placebo · For: Overactive Bladder (OAB)
Sites: Huntsville, Alabama; Mobile, Alabama; Anchorage, Alaska · 120 sites in all
- A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive BladderPivotal-lookingCompleted
Astellas Pharma China, Inc.Astellas (ALPMY)
NCT04562090 · 249 participants · Start Jan 6, 2021 · Primary completion Mar 17, 2022
Drug: mirabegron · For: Urge Incontinence; Overactive Bladder (OAB)
Sites: Wuhan, China; Beijing, China; Chengdu, China · 15 sites in all
- A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)Pivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT02656173 · 568 participants · Start Jan 25, 2016 · Primary completion Jul 21, 2017
Drug: Mirabegron; Placebo and 1 more · For: Overactive Bladder
Sites: Aichi, Japan; Chiba, Japan; Fukuoka, Japan · 58 sites in all
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT02757768 · 715 participants · Start Jun 13, 2016 · Primary completion Aug 14, 2018
Drug: Mirabegron; Placebo and 1 more · For: Benign Prostatic Hyperplasia; Overactive Bladder
Sites: Homewood, Alabama; Huntsville, Alabama; Anchorage, Alaska · 79 sites in all
Astellas Pharma Korea, Inc.Astellas (ALPMY)
NCT01747577 · 68 participants · Start Dec 4, 2012 · Primary completion Oct 24, 2013
Drug: Solifenacin Succinate; Placebo · For: Overactive Bladder; Benign Prostate Hyperplasia; Transurethral Resection of Prostate and 1 more
Sites: Seoul, South Korea
- Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.Pivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT02294396 · 649 participants · Start Oct 28, 2014 · Primary completion Sep 7, 2016
Drug: Mirabegron tablet; Solifenacin tablet and 3 more · For: Overactive Bladder (OAB)
Sites: Chugoku, Japan; Chūbu, Japan; Hokkaido, Japan · 7 sites in all
- Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic BladderCompleted
AbbVieAbbVie (ABBV)
NCT01192568 · 52 participants · Start May 17, 2011 · Primary completion Aug 29, 2023
Drug: Oxybutynin; Placebo · For: Overactive Detrusor; Neurogenic Bladder
Sites: Loma Linda, California; Orange, California; Aurora, Colorado · 10 sites in all
Kyowa Kirin China Pharmaceutical Co., Ltd.Industry
NCT03123406 · 750 participants · Start Apr 19, 2017 · Primary completion Apr 20, 2019
Drug: Cinacalcet HCl · For: Hyperparathyroidism; Secondary, Renal
Sites: Nanjing, China
AstraZenecaAstraZeneca (AZN)
NCT04655027 · 25 participants · Start Feb 22, 2021 · Primary completion Oct 12, 2021
Drug: Roxadustat; rHuEPO · For: Anemia of Chronic Kidney Disease
Sites: Baotou, China; Beijing, China; Guangzhou, China · 8 sites in all
- Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of HyperphosphatemiaPivotal-lookingCompleted
ArdelyxIndustry
NCT04549597 · 333 participants · Start Nov 20, 2020 · Primary completion Oct 13, 2021
Drug: Tenapanor · For: Chronic Kidney Disease Requiring Chronic Dialysis; Hyperphosphatemia
Sites: Lauderdale Lakes, Florida
OPKO Health, Inc.Industry
NCT03588884 · 69 participants · Start Jun 8, 2018 · Primary completion Apr 24, 2020
Drug: Calcifediol Oral Capsule; Calcifediol Oral Product and 2 more · For: Secondary Hyperparathyroidism Due to Renal Causes; Vitamin D Insufficiency; CKD Stage 3 and 1 more
Sites: Garden Grove, California; Chicago, Illinois; West Bend, Wisconsin
- Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney DiseasePivotal-lookingCompleted
Kyntra BioIndustry
NCT04059913 · 318 participants · Start Jun 11, 2019 · Primary completion Nov 19, 2021
Drug: Roxadustat · For: CKD Anemia in Dialysis Participants
Sites: Hefei, China; Lanzhou, China; Guangzhou, China · 25 sites in all
- Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on HemodialysisPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01227616 · 296 participants · Start Aug 2013 · Primary completion Feb 2016
Drug: Ferumoxytol; Iron Sucrose · For: Iron Deficiency Anemia Treatment; Chronic Kidney Disease(CKD)
Sites: Pine Bluff, Arkansas; Azusa, California; Beverly Hills, California · 43 sites in all
- Safety and Efficacy of Iron Sucrose in ChildrenPivotal-lookingCompleted
American Regent, Inc.Industry
NCT00239642 · 141 participants · Start Jul 2005 · Primary completion Jan 2009
Drug: Venofer (iron sucrose injection); Venofer (iron sucrose injection) and 1 more · For: Anemia; Chronic Kidney Disease
Sites: Norristown, Pennsylvania
Mallinckrodt ARD LLCIndustry
NCT02633046 · 63 participants · Start Oct 10, 2016 · Primary completion Aug 27, 2020
Drug: Acthar Gel · For: Idiopathic Focal Segmental Glomerulosclerosis
Sites: Birmingham, Alabama; Tucson, Arizona; Chula Vista, California · 47 sites in all
AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
NCT01506947 · 65 participants · Start May 10, 2012 · Primary completion Apr 7, 2016
Drug: Paricalcitol; Darbepoetin alfa · For: Moderate to Severe Secondary Hyperparathyroidism; Stage 5 Chronic Kidney Diseases
- Patiromer With or Without Food for the Treatment of HyperkalemiaPivotal-lookingCompleted
Relypsa, Inc.Industry
NCT02694744 · 114 participants · Start Feb 2016 · Primary completion Jul 2016
Drug: patiromer · For: Hyperkalemia
Sites: Fountain Valley, California; Huntington Beach, California; Palm Springs, California · 29 sites in all
- KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)Pivotal-lookingCompleted
Keryx BiopharmaceuticalsIndustry
NCT03236246 · 206 participants · Start Aug 15, 2017 · Primary completion Aug 30, 2019
Drug: KRX-0502 · For: Chronic Kidney Diseases; Iron Deficiency Anemia
Sites: Phoenix, Arizona; Chula Vista, California; El Centro, California · 28 sites in all
- Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)Pivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00143221 · 350 participants · Start Mar 2004
Drug: Viagra; Placebo · For: Impotence
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00648323 · 80 participants · Start Nov 2003
Drug: Doxazosin mysylate GITS · For: Prostate
Sites: Kaohsiung City, Taiwan; Taichung, Taiwan; Taipei, Taiwan · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.